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Rs320 and HindIIIa b s t r a c t
Lipoprotein Lipase (LPL) is known to be a key enzyme for lipid metabolism specifically in an enzymatic
glycoprotein which provide tissues without fatty-acids and eliminates triglycerides (TG) by the circula-
tion. Mutations in LPL were proven to cause alteration in fractions within lipoprotein, causing the devel-
opment of atherosclerosis which predispose to weakening coronary artery disease (CAD) and stroke. We
examined the linkage between genetic variant HindIII in LPL on lipoprotein fractions, stroke occurrences
and CAD. In this case-control study, we have recruited 315 CAD cases and 205 age-matched controls. A
total of 520 genomic DNA was digested with the purified PCR products for restriction fragment length
polymorphism with HindIII restriction enzyme. The distribution of genotypes in a decreasing order were
TT, 148 (47%), GT 135 (42.9%) and GG 32 (10.2%) in CAD groups of the study while the pattern in controls
were GT 91 (44.4%), TT 86 (42%) and GG 28 (13.7%). None of all the allele or genotype frequencies were
found to be significant in our study (p greater than 0.05), while the biochemical levels for both TG and
LDL-c were shown to be prone in CAD patients when compare with the controls. Furthermore, the occur-
ence of strokes were more in CAD groups vs. controls: 72 (22.9%) vs. 7 (3.4%) [p 0.000]. This could indicate
the influence of HindIII variant on plasma lipid levels, and the possibility of considering it a risk factor for
atherosclerosis leading to CAD and stroke occurrence.
 2020 The Author(s). Published by Elsevier B.V. on behalf of King Saud University. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Mammalian lipase family plays a vital role in sustaining normal
plasma levels, accountable for involving numerous enzymes such
as hepatic, endothelial, pancreatic, gastric and lipoprotein lipases
(LPL) (Nimonkar et al., 2020). The LPL deficiency is infrequently
inherited disease characterized by chylomicronemia, severe hyper-
triglyceridemia, and risk of recurrent pancreatitis (Han et al.,
2020). One of the key enzymes in LPL will regulate triglyceride
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(HDL-C) (Kochetova et al., 2019). LPL promotes modifies the lipids
between very low-density lipoprotein to HDLC (Su and Peng,
2020). Previous studies have discovered dyslipidemia as a risk fac-
tor in Coronary artery disease (CAD), which have been explored the
genetic role of polymorphisms in the LPL gene (Gerodias et al.,
2019). LPL plays the role of non-catalytic bridging as one of the
ligands in lipoprotein cell surface interaction in uptake of lipopro-
teins (Laufs et al., 2020). Enzymatic glycoprotein is known to be as
LPL, which involves 448 amino-acids with a very well significant
role in hydrolyzing triglycerides (TG) (Yamada, 2020). Genetic
modification in the LPL gene in which LPL low levels are associated
with one of the increased CAD risk factors (Xu et al., 2019). The
critical elevation in TG values were associated with molecular vari-
ants in the LPL gene which lower the LPL activities and due to this
LPL is linked with specific metabolic syndrome as type 2 diabetes
mellitus (T2DM), obesity and non-alcoholic fatty liver disease (de
Andrade Júnior, 2018; Khan et al., 2015). LPL plays an essential role
in lipoprotein metabolism as well as in chylomicrons. As per the
results, free fatty acids and monoglycerides are formed for usage
in energy production and storage. The LPL gene consists of 10
exons and 11 introns, which spans about 35 kilobases in size; the
accurate chromosomal location is at 8p22 and till now, more than
100 mutations have been identified. (Alinaghian et al., 2019).
Cardiac diseases are the combined combination of CAD and
hypertension for major causes of death (Kumar et al., 2020). The
CAD has been confirmed through the epidemiological studies as
multigene cum multifactorial regulated human disease (Fan
et al., 2020). The estimated mortality rate will be about 23 million
by 2030 (Zhang et al., 2019). Nine million deaths have been
recorded in all ages of subjects with CAD and known to be the
one of the cause of mortality global-wide (Zheng et al., 2020).
The major cause of CAD is atherosclerosis which further precede
for coronary heart disease (CHD). The appearance of atherosclero-
sis will be symptomatic phase and can confirmed as coronary
artery calcification in the CAD (Pechlivanis et al., 2020). CAD is
one type of cardiovascular disease that is affected due to a low
amount of oxygen and the appearance of blood in the heart
(Elnaggar et al., 2019). The combination of genetic and environ-
mental factors plays a significant role in the progression and
pathogenesis of CAD (Matam et al., 2015). Physical activity, diet
and smoking are the major flaws connected with environmental
causes (Yuan et al., 2020; Melam et al., 2016). T2DM is one of
the risk factor CAD, stroke and CHD events atleast through two-
to-three folds and simultaneously, T2DM have the maximum
chances of developing CAD which is highly tends to be a complex
disease (Khan et al., 2015; Naito and Kasai, , 2015). The etiology
of CAD is remains to be obscure and heritability rate was docu-
mented to be between 40 and 60% as per family and twin studies
(Lu et al., 2020).
Genome-wide association studies have identified numerous loci
for the CAD and one of the main susceptibility loci is placed at
chromosome 15q26.1 which exists the single nucleotide polymor-
phism in the form of rs17514846 (Yang et al., 2020). Several case-
control and meta-analysis studies have shown the relation
between LPL gene and CAD (Xu et al., 2019; Javorsky et al., 2007;
Daoud et al., 2013; Fischer et al., 2018; Ma et al., 2018; Shahid
et al., 2017; Xie, 2017). The accurate genetic and molecular or
any other mechanism which affects the LPL and human disease is
poorly understood and LDL was interrelated towards certain
heterogenous disorders which involve limited cardiovascular dis-
orders (Hartley et al., 2020). The rs320 polymorphism has been
studied globally in CAD, stroke, dyslipidemia (Javorsky et al.,
2007; Nejati et al., 2018; Sagoo et al., 2008; Samgina et al., 2016;
Tetik Vardarli et al., 2017; Velasquez Pereira et al., 2016) and this
polymorphism is located between the intron 6–8 and importantrole of rs320 polymorphism could elevate the atherosclerosis risk
through influencing plasma lipid levels (Nagrani et al., 2020). LPL
variants, Ser447stop (S447X) are connected to a decline in LPL
activity while Asn291Ser (N291S) and Asp9Asn (D9N) with an ele-
vation in LPL activity. Thus, these variants could affect lipid profile
levels and lead to CAD eventually (Bhanushali, 2010). A Prior study
results from Saudi Arabia have showed that significant linkage
occur between HindIII polymorphism (rs320), Ser447Ter Pvull
polymorphisms and changes in plasma lipids levels in CAD patients
(Daoud et al., 2013). Although the results from previous studies
have highlighted the role of polymorphisms at LPL gene in causing
CAD, not all of the polymorphisms have showed significant corre-
lations to CAD. Here, we study the effects of the genetic variant,
HindIII at the position 481 in intron 8 (T ? G), on lipid profile
levels and its association to CAD occurrence.2. Materials and methods
2.1. Study subjects
In this case-control study, we have selected 520 subjects
confirmed as 315 cases and 205 controls recruited during the
time-phrase of September-2013 to May-2015 from King Abdullah
Medical city (KAMC) and Al-Noor specialist hospitals appears at
the western region of Saudi Arabia. The inclusion criteria of the
CAD cases were based on complete investigation achieved in the
hospital premises. The age range of the involved cases were in
between 30 and 85 years of age with 50% higher than the stenosis
of coronary arteries. T2DM patients were confirmed through Amer-
ican Diabetes Association criteria (Khan et al., 2014), while dyslipi-
demia cases were confirmed by prior studies (Cleeman and
Grundy, 1997). Body Mass Index was calculated as per the
described study (Khan et al., 2016) and hypertension was deter-
mined as systolic blood pressure as  140 mmHg and diastolic
blood pressure as  90 mmHg (Alharbi et al., 2015; Poornima
et al., 2015). The age and gender controls were opted without
any histories of peripheral vascular disease, CAD and stroke.
Patients with malignancies and other auto-immune diseases were
also excluded from our study. Ethical grant was obtained from
Umm Al-Qura University-43430838 in 05/05/1434H and KAMC-
13–043. All the involved participants have signed the informed
consent form. All chosen methods were executed in accordance
with the relevant guidelines and regulations of Umm Al-Qura
University and King Abdullah Medical City. Documented and
enlightened consent was acquired from every study participant.
Data on diverse parameters such as age, sex, smoking, diet, height,
and weight were enrolled.
2.2. Biochemical assays
From each patient, 10 mL of blood sample was collected and
divided into serum and EDTA vacutainers (Khan et al., 2015). Five
mL of the serum sample was used for fasting glucose, lipid profiles
and cardiac markers; whereas the remaining 5 mL of the peripheral
blood was collected to extract the DNA. Biochemical analysis was
carried out with the described studies (Matam et al., 2015; Khan
et al., 2014).
2.3. Molecular assays
GeneJet-DNA extraction purification kit was used to isolate the
genomic DNA through the described protocol and stored in the
20 C for further usage. NanoDrop spectrophotometer was used
to measure the quality and quantity of the genomic DNA (Khan
et al., 2015). Genotyping was performed using polymerase chain
Table 1






Age (Mean ± SD) 59.7 (10.87) 58.4 (9.28) 0.157
BMI (Mean ± SD) 29.26 (4.11) 26.26 (6.49) 0.000
Gender (Male%) 206 (65.4%) 119 (58%) 0.055
Smoking (%) 150 (47.6%) 58 (28.3%) 0.000
Exercise (%) 72 (22.9%) 67 (32.7%) 0.009
Diabetes (%) 187 (59.4%) 35 (17.1%) 0.000
Fasting glucose (mg/dl) 140.64 83.56 0.000
Hypertension (%) 221 (70.2%) 41 (20%) 0.000
SBP (mmHg) 146.47 122.03 0.000
DBP (mmHg) 91.84 74.25 0.000
Event Stroke (%) 72 (22.9%) 7 (3.4%) 0.000
Total Cholesterol (mg/dl) 154.17 (23.6) 140.88 (18.09) 0.000
HDL-c (mg/dl) 39.95 (8.05) 41.14 (8.65) 0.111
LDL-c (mg/dl) 115.89 (38.28) 88.6 (30.18) 0.000
Triglycerides (mg/dl) 145.97 (60.27) 120.12 (22.71) 0.000
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analysis (Poornima et al., 2019). The primers for intron-8 region
of LPL gene was adopted from the prior studies (Javorsky et al.,
2007; Ahmadi et al., 2015; Lee et al., 2004). Amplification was per-
formed using GoTaq colorless master mix (Promega Co. Ltd) in a
thermal cycler (Khan et al., 2015). Primers yielded 770 bp as the
PCR fragment size. Next, undigested PCR products were digested
using 10U of HindIII restriction enzyme (New England BioLabs
Ltd) was added to make the final volume digested products for
25 mL and incubated at room-temperature for 60 min. PCR products
further were digested with 3% ethidium bromide stained in the
agarose gel (Khan et al., 2015). GG homozygotes were found to
be 770 bp; TT homozygotes were divided into 600/170 bp and
heterozygotes were found to be 770/600/170 bp respectively
(Fig. 1).
2.4. Data analysis
Statistical data was analysed using SPSS (version 23.0) and
Openepi softwares as described (Khan et al., 2019). Clinical data
was expressed as mean ± standard deviation. Genotype and allele
frequencies were calculated as per the presence of difference alle-
les observed and complete number of alleles inspected using odds
ratio’s (OR’s) and 95% confidence intervals (CI’s). Fischer’s exact t-
test were also attained. Non-parametric Krushkal Wallis test was
used to compare the mean ranks of skewed quantitative variables
in relation to the three products of) LPL gene G > T locus. (TT, GT &
GG). Significance was set-up as p < 0.05 (Khan et al., 2015).3. Results
The study recruited 315 coronary artery diseases patients with
more than 50% stenosis confirmed on coronary angiography and
205 aged-matched controls. The characteristics of the participants
(Table 1) revealed fairly equaled distribution by age as the patients
had mean age and SD of [59.7 (10.87)] versus that of controls of
[58.4 (9.28)] with a p value of 0.157. In addition, patients largely
demonstrated more characteristics than controls in the following
parameters: body mass index 29.26 (4.11) vs. 26.26 (6.49)
[p 0.000], smoking status 150 (47.6%) vs. 58 (28.3%) [p 0.000], exer-
cise habits 72 (22.9%) vs. 67 (32.7%) [p 0.009], diabetes mellitusFig. 1. Digested PCR products187 (59.4%) vs. 35 (17.1%) [p 0.000], and blood glucose levels
140.64 mg/dl vs. 83.56 mg/dl [p 0.000].
The presence of hypertension and events of stroke in patients as
compared to controls were statistically: hypertension 221 (70.2%)
vs. 41 (20%) [p 0.000], systolic pressure 146.47 vs. 122.03 mmHg
(p 0.000), diastolic pressure 91.84 vs. 74.25 mmHg (p 0.000), and
events of stroke 72 (22.9%) vs. 7 (3.4%) [p 0.000]. Furthermore, lipid
profile revealed significant difference in measured total choles-
terol, LDL, triglycerides and curiously the seemingly protective
HDL showed no dissimilarity between patients and controls.
The distribution of genotypes (Table 2) were in decreasing order
TT, 148 (47%), GT 135 (42.9%) and GG 32 (10.2%) in the cases of the
study while the pattern in controls were GT 91 (44.4%), TT 86 (42%)
and GG 28 (13.7%). Fig. 1 depicted the position of G and T alleles on
intron 8 of the LPL gene. Cases were likely than controls to have all
the genotypes in this study. Among the two of the genotypes of
HindIII, none were statistically significant as the odd ratios
between the cases and controls were as follows: TT [OR = 1.506,
95% CI (0.849–2.670), p 0.182] and GT [OR = 1.298, 95% CI
(0.732–2.301), p 0.227]. Alleles distribution among cases and con-
trols were more with T than G, however they were not statistically
significant as the OR = 0.826, 95%CI (0.635–1.074), p0.087.for HindIII polymorphism.
Table 2
Genotype and allele frequencies between CAD cases and control subjects.
Case (315) Control (205) OR 95% CI P
Genotypes No. % No. %
GG 32 10.2 28 13.7 1
GT 135 42.9 91 44.4 1.298 (0.732–2.301) 0.227
TT 148 47 86 42 1.506 (0.849–2.670) 0.182
Alleles
G 199 31.59 147 35.85 0.826 (0.635–1.074) 0.087
T 431 68.41 263 64.15
Table 3
Risk factors distribution across genotypes.
No. (%) TT GT GG P
Age [mean(SD)] 59.42 (11.28) 59.56 (10.55) 61.59 (10.40) 0.581
BMI (Kg/m2) [mean(SD)] 28.83 (3.9) 29.33 (4.11) 30.92 (4.74) 0.032
Gender (male %) 105 (33.33%) 85 (26.98%) 16 (5.08%) 0.057
Smoking 76 (24.13%) 64 (20.32%) 10 (3.17%) 0.118
Exercise (%) 35 (11.11%) 30 (9.52%) 7 (2.22%) 0.951
Hypertension (%) 99 (31.43%) 98 (31.11%) 24 (7.62%) 0.474
Systolic BP (mmHg) 146.47 (12.66) 147.04 (12.12) 144.01 (12.07) 0.462
Diastolic BP (mmHg) 92.03 (10.17) 90.58 (9.46) 92.70 (9.09) 0.349
Diabetes (%) 88 (27.94%) 77 (24.44%) 22 (6.98%) 0.479
Blood glucose (mg/dl) 141.46 (21.36) 140.32 (20.36) 138.18 (19.84) 0.701
Stroke (%) 41 (13.02%) 22 (6.98%) 9 (2.86%) 0.065
TC (mg/dL) 155.37 (22.48) 152.38 (24.79) 156.17 (23.70) 0.500
LDLc (mg/dL) 117.35 (43.35) 113.80 (24.79) 117.97 (45.72) 0.701
HDLc (mg/dL) 39.78 (8.55) 39.97 (7.50) 40.65 (8.13) 0.859
TG (mg/dL) 143.31 (59.34) 146.34 (59.91) 156.75 (66.50) 0.519
Table 4
Effects of environmental factors on plasma HDL-c levels.
Factor N HDL-c Mean difference -t P
Gender Male 206 37.43 ± 7.2  7.275  8.442 0.000
Female 109 44.71 ± 7.4
Obesity BMI < 30 kg/m2 185 40.06 ± 8.1 0.268 0.291 0.772
BMI  30 kg/m2 130 39.79 ± 8
Smoking Yes 150 39.51 ± 7.7 0.844 0.933 0.353
No 165 40.35 ± 8.3
Diabetes Yes 187 37.83 ± 7.6 5.23 5.968 0.000
No 128 43.06 ± 7.7
TG TG < 150 mg/dl 161 40.89 ± 7.8 1.93 2.14 0.033
TG  150 mg/dl 154 38.97 ± 8.2
Table 5
Regression analysis with associated risk factors.
Variables B Beta t P
LPL G Allele  0.001  0.008  0.459 0.046
Age 0.001 0.012 0.654 0.513
BMI 0.004 0.049 2.674 0.008
Smoking 0.31 0.031 1.355 0.176
Exercise  0.019  0.017  0.976 0.329
Hypertension 0.056 0.058 2.686 0.007
Systolic BP 0.008 0.256 11.114 0.000
Diastolic BP 0.007 0.191 8.972 0.000
DM 0.044 0.044 2.188 0.029
Fasting Glucose conc 0.007 0.472 18.896 0.000
TG 0.001 0.060 3.334 0.001
TC 0.001 0.060 3.341 0.001
LDL-c 0.001 0.064 3.462 0.001
HDL-c  0.001  0.012  0.687 0.049
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demonstrated insignificance except for BMI which showed differ-
ential change towards the GG genotype (p = 0.032). Analysis of
the effects of HDL-c across all patients (Table 4) revealed statisti-
cally significant difference for males (p = 0.000), diabetics(p = 0.000) and triglycerides < 150 mg/dl (p = 0.033). While no dif-
ferences were noted for obesity and smoking. Regression analysis
of associated factors in Table 5 demonstrated significance of G
Allele and other parameters except for age (p = 0.513), smoking
(p = 0.176) and exercise (p = 0.329).
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The aim of the present study was to investigate the genetic
association of rs320 polymorphism in LPL gene in the diagnosed
CAD cases in Saudi population. The results of this study confirm
the negative association either with allele or genotype frequencies
(p > 0.05) between the CAD cases and control subjects.
LPL is a key-enzyme for the lipid metabolism and it can hydro-
lyze the TG of chylomicrons and VLDL to provide free fatty-acids
for oxidation and exploitation in heart and other tissues for storing
in adipose tissues. LPL is a pathophysiological procedure for chy-
lomicronemia, diabetes, obesity and atherosclerosis. LPL gene is
cDNA translated into 475 amino-acid proteins which involves sig-
nal peptide of 27 amino-acids. RFLP in LPL gene has confirmed
BamHI, BstNI, HindIII, PvuII and Ser447X sites. HindIII is one of
the polymorphisms amongst in which plasma lipids were associ-
ated and lowers the plasma LPL activities; further subordinates
with high TG and low HDL-c levels which may contribute in the
CAD patients. The HindIII variant exists 495 bp from the intron-8
towards the splice site and effect the RNA splicing. The H-allele
in this variant may enhance the enzyme activity (Xie, 2017). How-
ever, other studies have confirmed various discrepancies regarding
the TG level, incidence of myocardial and rate of acute ischemic
strokes in different geographical locations and ethnicities.
Our study located in western part of Saudi Arabia revealed ele-
vated total cholesterol, low density cholesterol and triglycerides
among patients with coronary artery disease as compared. This is
conformity of the results in central province of Saudi Arabia where
CAD patients demonstrated drastically greater TG, TC and LDL-c
levels than controls in patientswithHindIII among other genotypes.
Furthermore, similar to our study, the genotypewas linkedwith sig-
nificantly reduced HDL-c levels. Both the studies have recognized
the connection between HindIII variant and high plasma levels in
TC, TG and LDL-c with low HDL-c levels (Daoud et al., 2013).
Despite the significant differences in lipid profile between cases
and controls, the HindIII polymorphism did not exert an indepen-
dent vulnerability to the development of CAD. Our study revealed
insignificant odd risk ratios among the haplotypes in both cases
and controls. The findings were similar to studies done among
Saudi population in central province of the country. Furthermore,
the frequencies of HindIII in our study (TT, 47.0; GT, 42.9 and
GG, 10.2%) were similar in these studies as Daoud et al. (Daoud
et al., 2013) recorded (TT, 45.1; TG, 35.8 and GG, 19%) while Abu
Amero et al. (Abu-Amero et al., 2003) reported slightly similar
(TT, 53.7; TG, 39.2 and GG, 7.1%). These studies proved the fact that
LPL-HindIII polymorphism could not be used as an independent
genetic risk factor for CAD in Saudi Arab populations. Both the
genetic and environmental factors like HTN, diabetes, obesity and
smoking are important risk-factors for the development of CAD.
In North Africa, the polymorphisms assessed by restriction assay
in 100 each of diabetic and non-diabetic Egyptian MI patients
and 100 healthy controls demonstrated that individuals with the
H2H2 genotype or S2 allele three times more likely to suffer from
MI than those carrying the H1H1 or S1S1 (El-Aziz et al., 2011).
Despite cultural linkage with the Saudi population, our study and
others did not show significant association between myocardial
infarction in patients with diabetes across all haplotypes of HindIII
polymorphism (Daoud et al., 2013; Abu-Amero et al., 2003).
In the Mediterranean area, a Spanish study which analysed var-
ious genetic variants including HindIII in a large, well-
characterized population, illustrated their association with TG
levels. The results demonstrated a liberated effect of the polymor-
phisms studied, notably TG-lowering HindIII case (Ariza et al.,
2010). The protective LPL variants HindIIIwere also shown in other
populations from southern Europe. In contrast, our study reportedraised levels of triglycerides. The differences may well be due to
the effects of geographical and ethnic dissimilarities between pop-
ulations of the studies. In conformity with our finding of dyslipi-
demia, an Iranian study which evaluated 725 children and
adolescents demonstrated the relationship of LPL HindIII [rs320]
and abnormal lipid levels (Marateb et al., 2018).
In an appraisal of the associations between seven LPL polymor-
phisms, lipid fractions and CHD risks in a population-based cohort,
case-control, and cross-sectional studies, Sagoo et al (Sagoo et al.,
2008) analysed populations comprising 22,734 CHD cases and
50,177 controls. The study reviewed the relationship between var-
ious polymorphisms including HindIII to TG, HDL-c, myocardial
infarction, or coronary stenosis. It was demonstrated that carriers
of the less common allele of HindIII depicted modestly advanta-
geous profiles. Furthermore, subset assessment of 8186 partici-
pants revealed that carriers of the less common allele of the
HindIII polymorphism higher HDL-c levels and lower TG levels than
non-carriers. The findings of our study conformedwith higher HDL-
c but at variance with lower triglyceride levels as themeta-analysis
was composed of large population of participants and varying geo-
graphic settings of white European continental ancestry, East Asian,
including Mexican-American and Turkish populations.
The event of acute stroke in our study though a small popula-
tion of participants was 22.9% in cases and 3.4% in controls with
a p Value of 0.000. In Colombia, Velasquez et al (Velasquez
Pereira et al., 2016), did not record any association between LPL
gene polymorphisms including HindIII and acute ischemic stroke
in the population studied (Velásquez Pereira and Vargas
Castellanos, 2016). In addition, the allele and genotypic frequencies
of the studied polymorphisms were similar in cases and controls.
However, in ameta-analysis of studies in five Chinese and Japanese
population, it was revealed that LPL-HindIII was protective factor
against stroke risk. Further stratification showed the protective
role played simultaneously for both hemorrhagic and ischemic
subtypes. It was postulated that rs320 produces a significant
impact on precursor RNA which may be a source of the protective
effect of the polymorphism in stroke propensity (Nejati et al.,
2018). Lipid profile in Colombian study were not significantly dif-
ferent between cases and controls despite the lack of association
between HindIII and the stroke risk. However, the controls had sta-
tistically significant high levels of HDL-c than the cases (Velásquez
Pereira and Vargas Castellanos, 2016).
The limitations of our study are; (i) we couldn’t provide the val-
idation results (ii) participants were recruited from couple of hos-
pitals placed in the western region and (iii) we miss the plasma
levels for LPL through Elisa. A multi-centre study would have in
addition, as in case-control studies, selection bias would have been
difficult to be avoided. The strength of our study is we have opted
good sample size with age and gender matched controls. Our study
couldn’t conclude the positive association with HindIII polymor-
phism in CAD patient and controls. However, other global studies
have confirmed as biomarker with rs320 or HindIII polymorphism.
At other angle, our study showed HindIII polymorphism in LPL
gene was associated with raised TG levels and stroke. However,
no associations were recorded with all haplotypes on the risk of
myocardial infarction, lipid profile and other established diseases
associated with myocardial infarction. Furthermore, the statistical
power of the study might be affected as cost was a mitigating fac-
tor in ensuring a ratio of 1:3 for cases and controls.Funding
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